Celcuity Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian F. Sullivan
- Full Time Employees
- 155
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2800 Campus Drive Minneapolis MN United States of America 55441
- IPO Date
- Sep 19, 2017
- CIK
- 0001603454
- Website
- celcuity.com
- Similar Companies
- Business
- Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer patients using its proprietary CELsignia platform to identify those most likely to benefit from specific treatments. The platform analyzes live tumor cells to measure signaling pathway activity, enabling precision oncology by matching patients to therapies based on tumor biology rather than traditional biomarkers. Core offerings include the CELsignia test service, which provides diagnostic signaling profiles for breast, lung, and other solid tumors; and its lead product candidate, gedatolisib, a pan-PI3K/mTOR inhibitor in Phase 1b/2 trials for hormone receptor-positive, HER2-negative breast cancer in combination with palbociclib and fulvestrant, as well as for other solid tumors. The company operates in the United States, with headquarters in Minneapolis, Minnesota, where it was founded in 2012. Recent developments include positive interim data from the VIKTORIA-1 Phase 2 trial of gedatolisib in November 2024, demonstrating significant progression-free survival benefits; expansion of the CELsignia platform to additional cancer indications; and ongoing collaborations with academic institutions and pharmaceutical partners for companion diagnostic development.
Company News
New Strong Sell Stocks for October 14th
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Celcuity Appoints David Gryska To Its Board Of Directors
Celcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy?
Why Celcuity Stock Was a Winner on Wednesday
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC
Celcuity: REVTORPYK Is Now A Commercial Story
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Q2 Earnings Call Highlights
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm